RapidAI announced it has received US Food and Drug Administration (FDA) 510(k) clearance for Rapid RV/LV, a tool that allows physicians to assess the ratio between the right ventricle (RV) and the left ventricle (LV), a key indicator of pulmonary embolism (PE) severity.
Rapid RV/LV uses AI to analyse computerised tomography pulmonary angiograms (CTPAs) and automatically calculate the RV/LV ratio within minutes of the scan, enabling physicians to more quickly conduct risk stratification for patients with right heart strain.
“Rapid PE streamlines the care pathway from the moment a suspected PE patient is scanned, to diagnosis and through treatment – reducing the complexities that come with managing PE, helping teams triage patients faster, and reducing overall time to treatment,” said Karim Karti, CEO of RapidAI. “The FDA clearance of Rapid RV/LV further enhances our PE solution by providing physicians with an immediate view into patients suffering from RV strain, which is critical to getting the right patients to the right care as fast as possible. This is yet another step toward delivering AI-based solutions that help physicians further enhance patient care and impact patient outcomes to ultimately improve quality of life – something we are very proud to be part of.”
“Elevated risk PE is a treatable disease, but it is underdiagnosed. Rapid RV/LV will be key in identifying PE patients with right heart strain,” said Peter Monteleone (Ascension Texas Cardiovascular, Austin, USA). “The ability to access the RV/LV ratio along with CTPA images will allow clinicians to quickly identify patients who would benefit from further treatment, improving patient outcomes and saving lives. This will have a profound impact on our PE programme here at Ascension.”
